A breakthrough product for the early detection of parietal lobe dysfunction and Alzheimer's disease, the AQT can be used in conjunction with brain imaging and other neuropsychiatric procedures to:
-
Support an early differential diagnosis of Alzheimer's disease
-
Detect impaired temporo-parietal function
Features and Benefits
Use this test with confidence when assessing you clients.
-
Contains rapid, automatic naming (RAN) tasks, verified by rCBF measures to screen for Alzheimer's disease and other parietal impairments
Tasks measure:
-
Processing speed and automaticity of naming
-
Cognitive shifts between visual dimensions and semantic fields
-
Activation of working memory for processing and monitoring
-
Parietal loble dysfunction associated with neurogenic disorders.
- Objective measures are based on clocked total-naming time
-
Highly reliable (r=.88 - 96) over time and consistent over repeated trials
-
Independent of gender differences, education and cultural linguistic background
-
Enables examiners from other cultural-linguistic communities to develop directions for administration and standards for verbal responses that are representative of their language
-
Allows you to conduct comparative evaluations of monolingual or bilingual adolescents and adults.